1446509-58-5

Usage

Uses

Used in Pharmaceutical Development:
2-(difluoromethyl)pyridin-4-amine is used as a building block for the synthesis of various pharmaceutical compounds. The difluoromethyl group in DFMPA can modulate the pharmacokinetic properties of the resulting molecules, which is essential for improving drug efficacy, bioavailability, and reducing side effects.
Used in Agrochemical Development:
2-(difluoromethyl)pyridin-4-amine is used as a starting material for the preparation of agrochemicals. Its unique chemical structure allows for the creation of compounds with specific pesticidal or herbicidal properties, contributing to the development of more effective and targeted agricultural products.
Used in Organic Synthesis:
2-(difluoromethyl)pyridin-4-amine is used as a reagent in various chemical reactions, facilitating the synthesis of a wide range of organic compounds. Its presence in these reactions can lead to the formation of new molecules with potential applications in various industries, including materials science and specialty chemicals.
Used in Drug Discovery:
2-(difluoromethyl)pyridin-4-amine is used as a starting material for the preparation of potential drug candidates. Its incorporation into molecular structures can lead to the discovery of new therapeutic agents with improved pharmacological properties, such as increased potency, selectivity, and reduced toxicity.

Upstream product

• 1192539-75-5 2-difluoromethylisonicotinic acid ethyl ester 
• 1256818-14-0 2-(difluoromethyl)isonicotinic acid 
• 1211580-54-9 4-bromo-2-(difluoromethyl)pyridine 

Relevant academic research and scientific papers

PYRAZOLO[1,5-D][1,2,4]TRIAZINE-5(4H)-ACETAMIDES AS INHIBITORS OF THE NLRP3 INFLAMMASOME PATHWAY

The invention relates to novel compounds for use as inhibitors of NLRP3 inflammasone production, wherein such compounds are as defined by compounds of formula (I) and wherein the integers R1, R2 and R3 are defined in the description, and where the compounds may be useful as medicaments, for instance for use in the treatment of a disease or disorder that is associated with NLRP3 inflammasome activity.

NOVEL PYRAZINE COMPOUNDS WITH OXYGEN, SULFUR AND NITROGEN LINKER FOR THE TREATMENT OF INFECTIOUS DISEASES

The present invention relates to compounds of the formula (I), or pharmaceutically acceptable salts, enantiomer or diastereomer thereof, wherein R1 to R3 are as described above. The compounds may be useful for the treatment or prophylaxis of hepatitis B virus infection.

SULPHAMOYLPYRROLAMIDE DERIVATIVES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B

Inhibitors of HBV replication of Formula (A) including stereochemically isomeric forms, and salts, hydrates, solvates thereof, wherein Ra to Rd, and R5 to R6 have the meaning as defined herein. The present invention also relates to processes for preparing said compounds, pharmaceutical compositions containing them and their use, alone or in combination with other HBV inhibitors, in HBV therapy.

NOVEL PYRAZOLO PYRIMIDINE DERIVATIVES AND THEIR USE AS MALT1 INHIBITORS

The present invention describes new pyrazolo-pyrimidine derivatives of formula (I) or a pharmaceutically acceptable salt thereof; (I) wherein, R1 is halogen, cyano, or C1-C3alkyl optionally substituted by halogen; R2 is C1-C6alkyl optionally substituted one or more times by C1-C6alkyl, C2-C6alkenyl, hydroxyl, N,N-di-C1-C6alkyl amino, N-mono-C1-C6alkyl amino, O-Rg, Rg, phenyl, or by C1-C6alkoxy wherein said alkoxy again may optionally be substituted by C1-C6alkoxy, N,N-di-C1-C6alkyl amino, Rg or phenyl; C3-C6cycloalkyl optionally substituted by C1-C6alkyl, N,N-di-C1-C6alkyl amino or C1-C6alkoxy-C1-C6alkyl, and/or two of said optional substituents together with the atoms to which they are bound may form an annulated or spirocyclic 4 - 6 membered saturated heterocyclic ring comprising 1 - 2 O atoms; phenyl optionally substituted by C1-C6alkoxy; a 5 - 6 membered heteroaryl ring having 1 to 3 heteroatoms selected from N and O said ring being optionally substituted by C1-C6alkyl which may be optionally substituted by amino or hydroxy; Rg; or N,N-di-C1-C6alkyl amino carbonyl; and R is phenyl independently substituted two or more times by Ra, 2-pyridyl independently substituted one or more times by Rb, 3-pyridyl independently substituted one or more times by Rc, or 4-pyridyl independently substituted one or more times by Rd; which are generally interacting with MALT1 proteolytic and/or autoproteolytic activity, and in particular which may inhibit said activity. The present invention further describes the synthesis of said new pyrazolo-pyrimidine derivatives, their use as a medicament, especially by interacting with MALT1 proteolytic and/or autoproteolytic activity.